REMARKS

Claims 55 to 57 are present.

Claim 56 is rejected under 35 U.S.C. §112, second paragraph. The Examiner contends that "Claim 56 recites the limitation 'R_a', third line from the bottom of Claim 56, page 3 of the amendment filed 10/22/04. There is insufficient antecedent basis for this limitation in the claim."

Claim 55 has been amended to replace $\stackrel{\longleftarrow}{\swarrow}_{\mathbf{x}}$ with $\mathbf{X}^1_{\mathbf{x}}$, $\stackrel{\longleftarrow}{\bigvee}_{\mathbf{m}}$ with $\mathbf{X}^1_{\mathbf{m}}$ and $\stackrel{\longleftarrow}{\bigvee}_{\mathbf{n}}$ with $\mathbf{X}^1_{\mathbf{n}}$.

Claim 56 has been amended as in Claim 55.

Basis for R_a is found in the Specification at page 4, lines 13 to 15.

Bases for the changes in the Specification are found at page 62, lines 4 and 5.

In view of the above amendments, it is clear that there is antecedent basis for R_a in Claim 55. Thus, Claim 56 (which depends from Claim 55) as now amended overcomes the objection under 35 U.S.C. §112 and is in condition for allowance.

The Examiner indicates that Claims 55 and 57 are allowed.

In view of the foregoing, it is believed that Claims 55 to 57 are in condition for allowance.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4336

Date: March 10,2005

Attorney for Applicants Reg. No. 22,076